Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ADMS
- CUSIP: N/A
- Web: www.adamaspharma.com
Capitalization:- Market Cap: $408.28 million
- Outstanding Shares: 22,359,000
Average Prices:- 50 Day Moving Avg: $17.40
- 200 Day Moving Avg: $16.84
- 52 Week Range: $12.10 - $19.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.67
- P/E Growth: -0.06
Sales & Book Value:- Annual Revenue: $397,000.00
- Price / Sales: 1,008.13
- Book Value: $5.36 per share
- Price / Book: 3.34
Profitability:- EBIDTA: ($64,670,000.00)
- Net Margins: -10,499.65%
- Return on Equity: -45.19%
- Return on Assets: -41.73%
Debt:- Current Ratio: 13.95%
- Quick Ratio: 13.95%
Misc:- Average Volume: 167,790 shs.
- Beta: 0.84
- Short Ratio: 16.03
Frequently Asked Questions for Adamas Pharmaceuticals (NASDAQ:ADMS)
What is Adamas Pharmaceuticals' stock symbol?
Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."
How were Adamas Pharmaceuticals' earnings last quarter?
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.72) EPS for the quarter, meeting the consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative return on equity of 45.19% and a negative net margin of 10,499.65%. During the same quarter in the prior year, the firm earned ($0.65) EPS. View Adamas Pharmaceuticals' Earnings History.
When will Adamas Pharmaceuticals make its next earnings announcement?
Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2017?
4 brokers have issued 12 month target prices for Adamas Pharmaceuticals' stock. Their predictions range from $26.00 to $45.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $35.50 in the next twelve months. View Analyst Ratings for Adamas Pharmaceuticals.
What are analysts saying about Adamas Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (7/11/2017)
- 2. Mizuho analysts commented, "We updated our model post-1Q:17 and the recent royalty financing." (6/6/2017)
Who are some of Adamas Pharmaceuticals' key competitors?
Some companies that are related to Adamas Pharmaceuticals include Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Intellia Therapeutics (NTLA), Mesoblast Limited (MESO), ANI Pharmaceuticals (ANIP), WAVE Life Sciences (WVE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), PDL BioPharma (PDLI), Abeona Therapeutics (ABEO) and Concert Pharmaceuticals (CNCE).
Who are Adamas Pharmaceuticals' key executives?
Adamas Pharmaceuticals' management team includes the folowing people:
- Gregory T. Went Ph.D., Chairman of the Board, Chief Executive Officer
- Alfred G. Merriweather, Chief Financial Officer
- Richard A. King, Chief Operating Officer
- Leonie McConville, Senior Vice President - Human Resources
- Natalie L. McClure Ph.D., Senior Vice President - Product Development
- Jennifer J. Rhodes, Chief Compliance Officer, General Counsel, Corporate Secretary
- Martin Forrest, Vice President, Corporate Communications and Investor Relations
- Rajiv Patni M.D., Chief Medical Officer
- David L. Mahoney, Lead Independent Director
- Michael F. Bigham, Director
Who owns Adamas Pharmaceuticals stock?
Adamas Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cheyne Capital Management UK LLP (0.49%), Private Asset Management Inc. (0.15%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Adamas Pharmaceuticals stock include Great Point Partners Llc, Gregory T Went, Ivan M Lieberburg, Ix Lp Mdv, Jennifer J Rhodes, Natalie Mcclure, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.
Who sold Adamas Pharmaceuticals stock? Who is selling Adamas Pharmaceuticals stock?
Adamas Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Cheyne Capital Management UK LLP. Company insiders that have sold Adamas Pharmaceuticals stock in the last year include Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and William J Dawson. View Insider Buying and Selling for Adamas Pharmaceuticals.
How do I buy Adamas Pharmaceuticals stock?
Shares of Adamas Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamas Pharmaceuticals' stock price today?
One share of Adamas Pharmaceuticals stock can currently be purchased for approximately $17.90.
MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)Earnings History by Quarter for Adamas Pharmaceuticals (NASDAQ ADMS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($0.81) | | | | | N/A |  |
| 5/9/2017 | Q1 2017 | ($0.72) | ($0.72) | $0.11 million | | View | Listen | |
| 2/28/2017 | Q4 | ($0.80) | ($0.68) | $0.17 million | $0.04 million | View | N/A | |
| 11/3/2016 | Q3 2016 | ($0.83) | ($0.66) | $0.26 million | $0.14 million | View | N/A | |
| 8/4/2016 | Q2 2016 | ($0.71) | ($0.78) | $0.18 million | $0.22 million | View | N/A | |
| 5/10/2016 | Q1 | ($0.76) | ($0.65) | | $0.18 million | View | N/A | |
| 2/23/2016 | Q4 | ($0.81) | ($0.58) | $0.10 million | $0.52 million | View | N/A | |
| 11/12/2015 | Q3 | ($0.79) | ($0.81) | $0.10 million | $0.77 million | View | N/A | |
| 8/11/2015 | Q215 | ($0.67) | ($0.78) | $0.10 million | $0.40 million | View | N/A | |
| 5/13/2015 | Q414 | ($0.74) | ($0.69) | $0.10 million | $0.23 million | View | N/A | |
| 3/3/2015 | Q4 2014 | $0.64 | $0.50 | $30.18 million | $30.30 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.44) | ($0.57) | $0.18 million | $0.22 million | View | N/A | |
| 8/7/2014 | Q214 | $2.07 | $0.88 | $18.75 million | $25.15 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.09) | ($0.67) | $30.60 million | $0.18 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)2017 EPS Consensus Estimate: ($3.48)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.64) | ($0.64) | ($0.64) |
| Q2 2017 | 1 | ($0.84) | ($0.84) | ($0.84) |
| Q3 2017 | 1 | ($0.96) | ($0.96) | ($0.96) |
| Q4 2017 | 1 | ($1.04) | ($1.04) | ($1.04) |
(Data provided by Zacks Investment Research)
Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Adamas Pharmaceuticals (NASDAQ:ADMS)Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 71.43%
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/21/2017 | Great Point Partners Llc | Major Shareholder | Sell | 380,000 | $17.08 | $6,490,400.00 | |
| 6/21/2017 | Jennifer J. Rhodes | Insider | Sell | 1,041 | $17.53 | $18,248.73 | |
| 6/19/2017 | Great Point Partners Llc | Major Shareholder | Sell | 350,000 | $17.05 | $5,967,500.00 | |
| 3/21/2017 | Gregory T Went | CEO | Sell | 2,807 | $17.03 | $47,803.21 | |
| 3/21/2017 | Rajiv Patni | Insider | Sell | 733 | $17.04 | $12,490.32 | |
| 3/21/2017 | William J Dawson | CFO | Sell | 716 | $17.02 | $12,186.32 | |
| 9/16/2016 | Ix Lp Mdv | Major Shareholder | Buy | 62,977 | $16.48 | $1,037,860.96 | |
| 9/13/2016 | Ix Lp Mdv | Major Shareholder | Buy | 84,376 | $15.58 | $1,314,578.08 | |
| 9/7/2016 | William W Ericson | Director | Buy | 60,846 | $15.68 | $954,065.28 | |
| 9/6/2016 | Ix Lp Mdv | Major Shareholder | Buy | 50,919 | $14.79 | $753,092.01 | |
| 9/6/2016 | William W Ericson | Director | Buy | 7,200 | $15.00 | $108,000.00 | |
| 9/2/2016 | William W Ericson | Director | Buy | 43,719 | $14.75 | $644,855.25 | |
| 4/18/2016 | Natalie Mcclure | SVP | Sell | 36,000 | $18.50 | $666,000.00 | |
| 12/7/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.23 | $48,690.00 | |
| 10/5/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.75 | $50,250.00 | |
| 9/8/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $19.13 | $57,390.00 | |
| 7/6/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $25.91 | $77,730.00 | |
| 6/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $18.95 | $37,900.00 | |
| 5/18/2015 | Ix Lp Mdv | Major Shareholder | Sell | 1,643 | $18.04 | $29,639.72 | |
| 5/15/2015 | Richard H Booth | Director | Sell | 1,000 | $17.85 | $17,850.00 | |
| 5/14/2015 | Gregory T Went | CEO | Sell | 2,728 | $18.00 | $49,104.00 | |
| 4/23/2015 | Gregory T Went | CEO | Sell | 3,300 | $18.00 | $59,400.00 | |
| 4/21/2015 | Gregory T Went | CEO | Sell | 962 | $18.01 | $17,325.62 | |
| 4/20/2015 | Gregory T Went | CEO | Sell | 2,610 | $18.00 | $46,980.00 | |
| 4/15/2015 | Richard H Booth | Director | Sell | 1,000 | $17.72 | $17,720.00 | |
| 4/14/2015 | Gregory T Went | CEO | Sell | 14,757 | $7.15 | $105,512.55 | |
| 4/10/2015 | William W Ericson | Director | Sell | 37,078 | $18.56 | $688,167.68 | |
| 4/6/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $17.44 | $52,320.00 | |
| 4/6/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $17.44 | $34,880.00 | |
| 3/19/2015 | Gregory T Went | CEO | Sell | 23,088 | $18.00 | $415,584.00 | |
| 3/18/2015 | Ix Lp Mdv | Major Shareholder | Sell | 11,723 | $18.02 | $211,248.46 | |
| 3/16/2015 | Richard H Booth | Director | Sell | 1,000 | $17.36 | $17,360.00 | |
| 3/13/2015 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 350,000 | $17.23 | $6,030,500.00 | |
| 2/17/2015 | Richard H Booth | Director | Sell | 1,000 | $16.54 | $16,540.00 | |
| 2/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $16.87 | $33,740.00 | |
| 2/2/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $16.77 | $50,310.00 | |
| 1/5/2015 | Ivan M Lieberburg | Director | Sell | 3,000 | $17.59 | $52,770.00 | |
| 1/5/2015 | Natalie Mcclure | SVP | Sell | 2,000 | $17.59 | $35,180.00 | |
| 12/24/2014 | Richard H Booth | Director | Sell | 2,000 | $17.51 | $35,020.00 | |
| 12/3/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 111,625 | $14.51 | $1,619,678.75 | |
| 12/1/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 13,615 | $14.54 | $197,962.10 | |
| 12/1/2014 | Natalie Mcclure | SVP | Sell | 20,000 | $14.50 | $290,000.00 | |
| 11/26/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 12,500 | $14.77 | $184,625.00 | |
| 11/25/2014 | Aeris Capital Equity Investmen | Major Shareholder | Sell | 10,000 | $14.85 | $148,500.00 | |
| 4/15/2014 | William W Ericson | Director | Buy | 300,000 | $16.00 | $4,800,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Adamas Pharmaceuticals (NASDAQ:ADMS)
Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
| Source: |
|
| Date | Headline |
|---|
 | Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:10 AM |
 | ETFs with exposure to Adamas Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:51 PM |
| Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - July 23 at 8:52 PM |
| Adamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : July 14, 2017
finance.yahoo.com - July 14 at 10:19 PM |
| ETFs with exposure to Adamas Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 5:18 PM |
 | Q3 Biotech Catalyst Watch: Key PDUFAs (Part 3)
seekingalpha.com - July 13 at 4:07 PM |
| Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : July 13, 2017
finance.yahoo.com - July 13 at 4:07 PM |
| Adamas Pharmaceuticals, Inc. (ADMS) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - July 11 at 11:26 PM |
| Adamas Reports Inducement Grant to New Chief Financial Officer
finance.yahoo.com - July 10 at 8:33 PM |
| Adamas Pharmaceuticals, Inc. (ADMS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 8:44 PM |
| -$0.85 EPS Expected for Adamas Pharmaceuticals, Inc. (ADMS) This Quarter
www.americanbankingnews.com - June 27 at 2:20 PM |
| Adamas Pharmaceuticals, Inc. (ADMS) Insider Jennifer J. Rhodes Sells 1,041 Shares
www.americanbankingnews.com - June 22 at 8:17 PM |
| Adamas Pharmaceuticals (ADMS) Presents At JMP Securities Life Sciences Conference 2017 - Slideshow
seekingalpha.com - June 22 at 12:52 PM |
| Adamas Pharmaceuticals, Inc. (ADMS) Major Shareholder Sells $5,967,500.00 in Stock
www.americanbankingnews.com - June 21 at 10:27 PM |
| Adamas Pharmaceuticals, Inc. (ADMS) Major Shareholder Sells $6,490,400.00 in Stock
www.americanbankingnews.com - June 21 at 10:27 PM |
| Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
finance.yahoo.com - June 13 at 5:40 AM |
 | Adamas Pharma (ADMS) Announces Expanded Analysis from the ADS-5102 Open-Label Study
www.streetinsider.com - June 9 at 3:25 PM |
| Adamas Provides Positive Long-term Data on Parkinson's Drug
finance.yahoo.com - June 9 at 3:25 PM |
| Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
finance.yahoo.com - June 8 at 8:26 PM |
| Adamas Pharmaceuticals (ADMS) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 1:27 AM |
| Adamas Pharmaceuticals Inc (ADMS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 6 at 8:33 PM |
| Adamas Pharmaceuticals Inc (ADMS) Earns "Buy" Rating from Mizuho
www.americanbankingnews.com - June 6 at 1:40 PM |
| Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : June 5, 2017
finance.yahoo.com - June 5 at 1:39 PM |
| Adamas to Present at Two Upcoming Investor Conferences
finance.yahoo.com - June 1 at 3:28 PM |
| Adamas Pharmaceuticals Inc (ADMS) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - June 1 at 12:30 PM |
| Cowen and Company Reaffirms "Outperform" Rating for Adamas Pharmaceuticals Inc (ADMS)
www.americanbankingnews.com - May 28 at 10:54 AM |
| Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
finance.yahoo.com - May 23 at 3:22 PM |
| Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
finance.yahoo.com - May 22 at 3:21 PM |
| Adamas Pharmaceuticals Inc (ADMS) Stock Rating Reaffirmed by Noble Financial
www.americanbankingnews.com - May 13 at 11:32 AM |
| Adamas Pharmaceuticals Inc (ADMS) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 8:56 PM |
| Adamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 12 at 6:42 PM |
| Adamas Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.84) Per Share, William Blair Forecasts (ADMS)
www.americanbankingnews.com - May 12 at 10:42 AM |
| Adamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 3:35 PM |
 | Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
globenewswire.com - May 11 at 3:35 PM |
| Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners
finance.yahoo.com - May 11 at 3:35 PM |
| Edited Transcript of ADMS earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 3:35 PM |
| [$$] Adamas Receives $100 Million Royalty-Backed Financing From HealthCare Royalty Partners
finance.yahoo.com - May 11 at 3:35 PM |
| Adamas Pharmaceuticals Inc (ADMS) Releases Earnings Results, Hits Expectations
www.americanbankingnews.com - May 10 at 9:14 PM |
| Adamas Pharmaceuticals Inc (ADMS) Expected to Post Quarterly Sales of $580,000.00
www.americanbankingnews.com - May 10 at 11:34 AM |
| Adamas Reports Recent Achievements and First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:21 PM |
 | Adamas reports 1Q loss
marketbeat.com - May 9 at 6:45 PM |
| Investor Network: Adamas Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 3:20 PM |
| Analysts Expect Adamas Pharmaceuticals Inc (ADMS) to Announce -$0.72 EPS
www.americanbankingnews.com - May 8 at 10:50 AM |
| Adamas Pharmaceuticals Inc (ADMS) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:02 AM |
| Adamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : May 5, 2017
finance.yahoo.com - May 5 at 8:21 PM |
| Adamas Reports Inducement Grant to New Chief Operating Officer
finance.yahoo.com - May 5 at 8:21 PM |
| Adamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : May 4, 2017
finance.yahoo.com - May 4 at 3:21 PM |
| Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
finance.yahoo.com - May 3 at 6:59 AM |
| Adamas Pharmaceuticals (ADMS) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - May 2 at 9:18 AM |
| Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102
finance.yahoo.com - April 27 at 8:39 PM |
Adamas Pharmaceuticals (ADMS) Chart for Thursday, July, 27, 2017
